Type-2 Diabetes
Conditions
Brief summary
This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.
Interventions
DRUGvildagliptin
Sponsors
Novartis
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
(general): * Men and women (age 18 to 85 years) * Participants must be nonfertile or using a medically approved birth control method. Additional information regarding this requirement available at screening * Body mass index (BMI) ≤42 kg/m2 (inclusive) Inclusion Criteria (for renal insufficient patients): * Patients with mild, moderate, or severe kidney impairment. Please consult with participating physicians regarding the definitions of these levels of severity. * Patients with diabetes must be treated with standard anti-diabetic therapy (diet and exercise, stable dose of sulfonylurea, insulin, or metiglinides) and agree to continue for the study duration Inclusion Criteria (for healthy subjects): * No current significant medical conditions as determined by history and physical. * Serum creatinine with a calculated creatinine clearance (CrCl) of \>80 ml/min. * Matched to renal impaired patients in the study by age (±5 years), sex and weight (±10% BMI) * Vital signs guided by the following ranges: oral body temperature between 35.0-37.2 °C systolic blood pressure, 100-140 mm Hg diastolic blood pressure, 60-110 mm Hg pulse rate, 45-90 bpm
Exclusion criteria
* Pregnant or lactating female. * A history of type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, acute metabolic diabetic complications (eg, ketoacidosis or hyperosmolar state (coma)) * Subjects that have been enrolled in previous vildagliptin studies or other DPP * 4 inhibitor studies within six months * History of renal transplant or immunosuppressant therapy * Acute infections which may affect blood glucose control or other medical condition that may interfere with the interpretation of efficacy and safety data during the study * Any pre-existing or history of diabetic ulcer * Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery or percutaneous coronary intervention, unstable angina or stroke * Any of the following electrocardiogram (ECG) abnormalities: Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation, second degree atrioventricular (AV) block (Mobitz 1 and 2), third degree AV block, prolonged QTc (\>500 ms) * Malignancy including leukemia and lymphoma within the last 5 years. * Liver disease such as cirrhosis or positive hepatitis B and C. * Any alcohol related hepatic disease. * Patients undergoing any method of dialysis * Use of some concomitant medications * Significant laboratory abnormalities as specified in the protocol * History of active substance abuse (including alcohol) within the past 2 years. * Smokers (i.e., 10 or more cigarettes per day) * History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Pharmacokinetic measures | throughout the study |
Secondary
| Measure | Time frame |
|---|---|
| • Safety and tolerability measures | throughout the study |
Countries
Germany, United States
Outcome results
None listed